Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 1Phase 2 Interventional

Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia

ClinicalTrials.gov ID: NCT00109356

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00109356. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open Label, Dose Escalation Study of AQ4N for Safety, Tolerability, Pharmacokinetics and Activity in Patients With Lymphoid Neoplasms

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find answers to the following questions: * What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks? * What are the side effects of AQ4N when given according to this schedule? * How much AQ4N is in the blood at certain times after administration and how does the body get rid of the drug? * Will AQ4N help treat lymphoid cancer?

Study identification

NCT ID
NCT00109356
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Novacea
Industry
Enrollment
55 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2005 (Type not available)
Primary completion
Not listed
Completion
Mar 2007 (Type not available)
Last update posted
May 7, 2007

2005 – 2007

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00109356, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2007 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.